skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8847

Biphasic insulin aspart 30/70 (BIAsp 30) in the treatment of type 1 and type 2 diabetes

Review

(3978) Views  (1086) Full article downloads

Authors: Paul Valensi

Published Date June 2009 Volume 2009:2 Pages 61 - 71
DOI: http://dx.doi.org/10.2147/DMSO.S3408

Paul Valensi

Department of Endocrinology-Diabetology-Nutrition, Jean Verdier Hospital, AP-HP, Paris Nord University, CRNH-IdF, Bondy, France

Abstract: The pharmacological advantages of the rapid-acting analog, insulin aspart, over human insulin have contributed to the widespread prescription of the premix, biphasic insulin aspart 30/70 (BIAsp 30), in type 1 (T1DM) and type 2 diabetes (T2DM). This article reviews the available literature on the pharmacology, efficacy and safety of BIAsp 30 in T1DM and T2DM from an online search of the PubMed database. Following injection, BIAsp 30 reaches higher plasma insulin levels more quickly than human premix or basal insulin, giving effective reduction of postprandial hyperglycemia. In T1DM patients, randomized controlled trials (RCTs) have shown that HbA1c reduction is similar, but postprandial glycemic control is better, with BIAsp 30 than with human insulin regimens. In T2DM patients, lowering of HbA1c and postprandial hyperglycemia with BIAsp 30 compare favorably with optimized oral antidiabetes drug treatment, insulin glargine, and, in obese patients, human premix. An increase in minor hypoglycemia with BIAsp 30 relative to basal insulin has been reported in T2DM patients, but major and nocturnal hypoglycemia rates are generally low. Findings from RCTs in T2DM patients are supported by large observational studies. In summary, BIAsp 30 once to three times daily represents a simple and effective tool for the modern management of diabetes.

Keywords: biphasic insulin aspart, BIAsp 30, premix, type 1 diabetes, type 2 diabetes








Readers of this article also read:

Sitagliptin as combination therapy in the treatment of type 2 diabetes mellitus
Alogliptin: a new addition to the class of DPP-4 inhibitors
Impact of obesity and type 2 diabetes on health-related quality of life in the general population in England
Management of obesity, insulin resistance and type 2 diabetes in children: consensus and controversy
Amantadine reduces glucagon and enhances insulin secretion throughout the oral glucose tolerance test: central plus peripheral nervous system mechanisms
Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes – a review
A retrospective database analysis of insulin use patterns in insulin-naïve patients with type 2 diabetes initiating basal insulin or mixtures
Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes
Insulin therapy in critically ill patients
Lixisenatide: evidence for its potential use in the treatment of type 2 diabetes
  • Testimonials

    "You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio